These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 16505207

  • 1. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
    Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S.
    Hypertension; 2006 Apr; 47(4):699-705. PubMed ID: 16505207
    [Abstract] [Full Text] [Related]

  • 2. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C, VIVALDI investigators.
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [Abstract] [Full Text] [Related]

  • 3. ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
    Böger RH, Schwedhelm E, Maas R, Quispe-Bravo S, Skamira C.
    Vasc Med; 2005 Jul; 10 Suppl 1():S97-102. PubMed ID: 16444875
    [Abstract] [Full Text] [Related]

  • 4. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A, Tabata M, Hayashi K, Saruta T.
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [Abstract] [Full Text] [Related]

  • 5. Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy.
    Yoshida S, Hashimoto T, Kihara M, Imai N, Yasuzaki H, Nomura K, Kiuchi Y, Tamura K, Ishigami T, Hirawa N, Toya Y, Kitamura H, Umemura S.
    Nephron Exp Nephrol; 2009 Sep; 111(1):e20-30. PubMed ID: 19052474
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S.
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [Abstract] [Full Text] [Related]

  • 8. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Katayama S, Yagi S, Yamamoto H, Yamaguchi M, Izumida T, Noguchi Y, Inaba M, Inukai K.
    Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
    [Abstract] [Full Text] [Related]

  • 9. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
    Yoneda T, Takeda Y, Usukura M, Oda N, Takata H, Yamamoto Y, Karashima S, Yamagishi M.
    Am J Hypertens; 2007 Dec; 20(12):1329-33. PubMed ID: 18047925
    [Abstract] [Full Text] [Related]

  • 10. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
    Ogawa S, Mori T, Nako K, Ito S.
    Hypertens Res; 2008 Jun; 31(6):1147-55. PubMed ID: 18716362
    [Abstract] [Full Text] [Related]

  • 11. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
    Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosoya T.
    Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy.
    Imanishi M, Okada N, Konishi Y, Morikawa T, Maeda I, Kitabayashi C, Masada M, Shirahashi N, Wilcox CS, Nishiyama A.
    J Renin Angiotensin Aldosterone Syst; 2013 Mar; 14(1):67-73. PubMed ID: 22859713
    [Abstract] [Full Text] [Related]

  • 13. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
    Liao J, Kobayashi M, Kanamuru Y, Nakamura S, Makita Y, Funabiki K, Horikoshi S, Tomino Y.
    J Nephrol; 2003 Mar; 16(6):841-9. PubMed ID: 14736011
    [Abstract] [Full Text] [Related]

  • 14. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
    Okura T, Kojima M, Machida H, Sugiyama M, Kato T, Komada T, Miyazaki T, Ninomiya T, Ichikawa T, Nakatani K, Watanabe Y, Dohi Y, Ito M, Kimura G.
    J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
    [Abstract] [Full Text] [Related]

  • 15. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
    Shigenaga A, Tamura K, Dejima T, Ozawa M, Wakui H, Masuda S, Azuma K, Tsurumi-Ikeya Y, Mitsuhashi H, Okano Y, Kokuho T, Sugano T, Ishigami T, Toya Y, Uchino K, Tokita Y, Umemura S.
    Nephron Clin Pract; 2009 Apr; 112(1):c31-40. PubMed ID: 19342867
    [Abstract] [Full Text] [Related]

  • 16. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
    Yu Y, Fukuda N, Yao EH, Matsumoto T, Kobayashi N, Suzuki R, Tahira Y, Ueno T, Matsumoto K.
    Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
    Savoia C, Touyz RM, Volpe M, Schiffrin EL.
    Hypertension; 2007 Feb; 49(2):341-6. PubMed ID: 17159079
    [Abstract] [Full Text] [Related]

  • 18. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, Kawasaki M, Nishigaki K, Takemura G, Fujiwara H.
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [Abstract] [Full Text] [Related]

  • 19. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A, Battegay E.
    Praxis (Bern 1994); 2005 Apr 13; 94(15):581-94. PubMed ID: 15884724
    [Abstract] [Full Text] [Related]

  • 20. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P, Andersen S, Jensen BR, Parving HH.
    J Am Soc Nephrol; 2003 Apr 13; 14(4):992-9. PubMed ID: 12660333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.